SeaStar Medical (ICU) files 8-K/A to correct EDGAR item references

SeaStar Medical Holding Corporation filed an amendment to its current report to correct an inadvertent EDGAR submission header so the filing references Items 2.02 and 9.01.

Rhea-AI Filing Summary

SeaStar Medical Holding Corporation filed an amendment to its current report to correct an inadvertent EDGAR submission header so the filing references Items 2.02 and 9.01. The amendment states it makes no changes to the substance of the original report.

The original report furnished a press release as Exhibit 99.1 announcing the company's financial condition and results for the three and six months ended June 30, 2025.

Positive

• EDGAR header corrected so the submission references the appropriate Item numbers (Items 2.02 and 9.01).
• Press release furnished as Exhibit 99.1 reporting the company's financial condition and results for the three and six months ended June 30, 2025.

Negative

• None.

Insights

Securities Analyst

TL;DR: This is an administrative correction; substantive disclosures unchanged and a press release on quarterly results was furnished as an exhibit.

The amendment corrects an EDGAR header referencing the wrong Item number and confirms no changes to the original 8-K content. Because the filing only updates metadata and reiterates that the press release is furnished rather than filed, there is minimal direct impact on the company's financial disclosures or investor valuation based on this amendment alone.

Corporate Governance Expert

TL;DR: Correcting filing metadata improves disclosure accuracy but does not alter the companys reported information; governance impact is procedural.

The amendment addresses an inadvertent EDGAR submission error to reference Items 2.02 and 9.01 correctly. This is a governance/administrative fix that enhances the accuracy of public records. It explicitly states there are no substantive changes to the original filing, so it should not affect the companys regulatory standing or change investor assessment based on the original disclosures.

8-K Event Classification

3 items: 2.01, 2.02, 9.01

3 items

Item 2.01 Completion of Acquisition or Disposition of Assets Financial

The company completed a significant acquisition or sale of business assets.

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the SeaStar Medical (ICU) 8-K/A amend?

The amendment corrects an inadvertent EDGAR submission header that referenced the wrong Item number and updates the header to reference Items 2.02 and 9.01; it does not change the original filing's disclosures.

Does this 8-K/A change SeaStar's reported financial results?

No. The amendment explicitly states there are no changes to the original filing and does not modify or update the disclosures about results of operations or financial condition.

What exhibit was furnished with the original report?

Exhibit 99.1 is a press release dated August 13, 2025 announcing SeaStars financial condition and results for the three and six months ended June 30, 2025; Exhibit 104 is the cover page interactive data file.

Is the press release considered filed or furnished under the Exchange Act?

The filing states the information, including the press release furnished as Exhibit 99.1, is deemed "furnished" and not "filed" for purposes of Section 18 of the Exchange Act.

Who signed the amendment for SeaStar Medical?

The amendment was signed by Eric Schlorff, Chief Executive Officer on behalf of SeaStar Medical Holding Corporation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/14/2025 - 09:07 AM Learn about SEC filing dates

0001831868true0001831868us-gaap:WarrantMember2025-08-132025-08-1300018318682025-08-132025-08-130001831868us-gaap:CommonStockMember2025-08-132025-08-13

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K/A

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 13, 2025

SeaStar Medical Holding Corporation

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-39927	85-3681132
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
3513 Brighton Blvd, Suite 410
Denver, Colorado				80216
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 844 427-8100

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock par value $0.0001 per share		ICU		The Nasdaq Stock Market LLC
Warrants, each whole warrant exercisable for one share of Common Stock for $11.50 per share		ICUCW		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Explanatory Note

This Amendment No. 1 to Form 8-K (this "Amendment") amends Form 8-K of SeaStar Medical Holding Corporation (the "Company") that was originally filed with the Securities and Exchange Commission on August 13, 2025, (the "Original Filing"). This Amendment is being filed solely to correct an inadvertent error in the submission of the Original Filing through EDGAR which referenced the incorrect Form 8-K Item Number (Item 2.01) in the EDGAR submission header. This Amendment is being filed through EDGAR to reference the correct Form 8-K Item Numbers (Items 2.02 and 9.01) in the EDGAR submission header. There are no changes to the Original Filing itself (which referenced the correct Item numbers). Except as summarized above, this Amendment continues to speak as of the date of the Original Filing and does not reflect events occurring after the date of the Original Filing or modify or update the disclosures therein in any way.

Item 2.02 Results of Operations and Financial Condition.

On August 13, 2025, the Company issued a press release announcing its financial condition and results of operations for the three and six months ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1.

The information in this Current Report on Form 8-K, including the information contained in the press release furnished as Exhibit 99.1, is deemed to be “furnished” and not “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is not otherwise subject to the liabilities of that Section, and shall not be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release dated August 13, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			SeaStar Medical Holding Corporation
		By:	/s/ Eric Schlorff
Date:	August 14, 2025	Name:	Eric Schlorff
		Title:	Chief Executive Officer